American Century Companies Inc. Sells 51,490 Shares of Vera Therapeutics, Inc. $VERA

American Century Companies Inc. trimmed its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 12.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 377,450 shares of the company’s stock after selling 51,490 shares during the quarter. American Century Companies Inc. owned about 0.59% of Vera Therapeutics worth $9,066,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of VERA. Vestal Point Capital LP bought a new position in Vera Therapeutics during the fourth quarter worth about $45,462,000. Integral Health Asset Management LLC increased its position in Vera Therapeutics by 130.0% during the fourth quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company’s stock worth $48,634,000 after acquiring an additional 650,000 shares during the period. Paradigm Biocapital Advisors LP increased its holdings in Vera Therapeutics by 31.0% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company’s stock valued at $60,785,000 after buying an additional 340,488 shares during the period. MPM Bioimpact LLC bought a new position in Vera Therapeutics in the 4th quarter valued at about $10,902,000. Finally, Balyasny Asset Management L.P. increased its holdings in Vera Therapeutics by 119.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 385,425 shares of the company’s stock valued at $16,300,000 after buying an additional 209,834 shares during the period. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Trading Up 5.6%

Shares of Vera Therapeutics stock opened at $22.54 on Wednesday. The firm has a market capitalization of $1.44 billion, a PE ratio of -6.30 and a beta of 1.17. The company has a current ratio of 17.03, a quick ratio of 17.03 and a debt-to-equity ratio of 0.16. The firm’s 50 day moving average is $22.13 and its 200 day moving average is $23.86. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same quarter in the prior year, the company earned ($0.62) EPS. Equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Patrick G. Enright purchased 40,607 shares of the firm’s stock in a transaction that occurred on Tuesday, June 24th. The shares were bought at an average cost of $22.35 per share, with a total value of $907,566.45. Following the acquisition, the director owned 3,596,593 shares of the company’s stock, valued at $80,383,853.55. This trade represents a 1.14% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 16.30% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on VERA. Guggenheim reissued a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Scotiabank reissued an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Cantor Fitzgerald decreased their target price on shares of Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th. Wedbush decreased their target price on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $85.00 target price (up from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Vera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $63.00.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.